Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5

Rothenberg, Marc E; Roufosse, Florence; Faguer, Stanislas; Gleich, Gerald J; Steinfeld, Jonathan; Yancey, Steven W; Mavropoulou, Eleni; Namhee, Kwon; Hes Mepolizumab Study Group: Gabriel Ricardo García,; Sosso, Adriana; Wehbe, Luis; Yañez, Anahí; Blockmans, Daniël; Roufosse, Florence; Martti Anton Antila,; Blanco, Daniela; Grava, Sergio; Marina Andrade Lima,; Andreia Luisa Francisco Pez,; Faguer, Stanislas; Mohamed, A Hamidou; Kahn, Jean-Emmanuel; Lefévre, Guillaume; Brockow, Knut; Peter, M Kern; Andreas, J Reiter; Walz, Bastian; Welte, Tobias; Pane, Fabrizio; Vannucchi, Alessandro Maria; Cerino-Javier, Ruth; Gazca-Aguilar, Alfredo; Dante, D Hernández-Colín; Héctor Glenn Valdéz-López,; Izabela, R Kupryś-Lipińska; Musial, Jacek; Prejzner, Witold; Mihaly, Eniko; Popov, Viola; Mihnea Tudor Zdrenghea,; Sergey, V Gritsaev; Ivanov, Vladimir; Tsyba, Nikolay; Alonso, Aránzazu; Maria Cinta Cid Xutgla,; Maria Laura Fox,; Regina Garcia Delgado,; Jesús María Hernández Rivas,; Guillermo Sanz Santillana,; Ana Isabel González,; Andrew, J Wardlaw; Akuthota, Praveen; Joseph, H Butterfield; Geoffrey, L Chupp; John, B Cox; Gerald, J Gleich; Jhaveri, Devi; Marc, E Rothenberg

doi:10.1016/j.jaip.2022.04.037

Mepolizumab, an anti-interleukin-5 (IL-5) antibody, reduces disease flares in patients with hypereosinophilic syndrome (HES). Factors predicting treatment response are unknown.

Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5 / Rothenberg, M.E., Roufosse, F., Faguer, S., Gleich, G.J., Steinfeld, J., Yancey, S.W., Mavropoulou, E., Kwon, N.. - In: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE. - ISSN 2213-2198. - ELETTRONICO. - 10:(2022), pp. 2367-2374.e3. [10.1016/j.jaip.2022.04.037]